Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07593053 2026-05-22

PIPO

Completed

586 enrolled

Tumor-Agnostic

Neoplasms

NCT06502691 2026-05-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Phase 1/2 Recruiting

22 enrolled

Breast

Breast Neoplasms

NCT05615142 2026-05-11

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Phase 1 Active not recruiting

9 enrolled

Thoracic

NSCLC

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Phase 3 Recruiting

380 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07572864 2026-05-11

Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

Phase 2 Recruiting

9 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06431685 2026-05-08

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Phase 1 Recruiting

10 enrolled

CNS

Meningeal Carcinomatosis

NCT07466238 2026-05-08

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Phase NA Recruiting

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT07574047 2026-05-07

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

Phase 4 Not yet recruiting

108 enrolled

Dermatologic

Melanoma

NCT07570849 2026-05-06

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT06349837 2026-05-01

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase 1 Recruiting

24 enrolled

Other solid neoplasm

Solid Tumor

NCT07007182 2026-05-01

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2 Recruiting

54 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07555678 2026-04-29

Chase

Phase 2 Recruiting

241 enrolled

Gastrointestinal

Anus Neoplasms

NCT07551479 2026-04-24

TORCH-STAR

Phase 3 Not yet recruiting

612 enrolled

Spinocerebellar Degenerations

NCT07541755 2026-04-21

PD1-VEN-CAG

Phase 3 Active not recruiting

40 enrolled

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06964568 2026-04-17

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Phase 3 Recruiting

452 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT07535944 2026-04-17

ICI-Vasc

Not yet recruiting

200 enrolled

Vascular Complications

NCT07519486 2026-04-15

INS-ESCC-CT

Phase 2 Recruiting

118 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06281405 2026-04-03

TORCH-iTNT

Phase 2 Recruiting

192 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT07486492 2026-03-20

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

Phase EARLY_PHASE1 Not yet recruiting

10 enrolled

Gastrointestinal

Colorectal Cancer Metastatic

NCT04943848 2026-03-17

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Phase 1 Recruiting

36 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

Clinical Trials

RAIRI-NPC

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

OPTICAL-3

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

PIPO

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Chase

TORCH-STAR

PD1-VEN-CAG

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

ICI-Vasc

INS-ESCC-CT

TORCH-iTNT

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG